Organisation paid for research Program year 2025 Source: CMS Open Payments

Lenus Research

Neither a doctor nor a teaching hospital

Research payments

$560,869

23 payments

Through program year 2025, Lenus Research is reported as receiving $560,869 in research payments, across 23 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$184,066	10
2024	Research	$308,158	5
2023	Research	$2,937	1
2021	Research	$26,328	3
2020	Research	$19,130	2
2019	Research	$20,250	2

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $490,695 14 payments
Incyte Corporation $41,985 4 payments
E.R. Squibb & Sons, L.L.C. $26,660 4 payments
AbbVie, Inc. $1,529 1 payment

Studies the money was for Research payments · program years 2019–2025

A Double-Blind, Double Dummy, Randomized, Phase 1B, Nitrofurantoin Con $423,528 7 payments
A Phase 3B, Open-Label, Single-Arm Study in Adolescent and Adult Femal $67,166 7 payments
A Phase 2, Double Blind, Dose Ranging, Placebo Controlled Study With Open Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis $41,985 4 payments
Phase 2 UC $13,531 1 payment
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis $12,937 2 payments
A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata $1,529 1 payment
Phase 2 UC Primary represents Induction $192 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.